NR4A1 and breast cancer: In recent years, a range of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been identified as significantly improving the survival of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC).